AmorChem Ventures: The Translational Venture Fund

AmorChem

• Who we are • What we do • What we have• Assets to highlight

– Mucoadhesive nanoparticles– Semaphorin 3a– OXO-ETE

3

• Sourced fromQuébec-baseduniversities and research centres

INTELLECTUAL PROPERTY

• Wholly-ownedsubsidiary

• Med chem CRO

NUCHEM• Company structure

to hold licenses• Fiscal structure for

research tax credits

AMORCHEM HOLDING

• Venture capital activity for commercialisation and business development

AMORCHEM VENTURE

AmorChem Ventures is the first and only venture fund In Canada dedicated to translating early academic science

into commercial innovation

Seed financing and incubation of university technologies are at the core of the AmorChem model

The principals behind the AmorChem model

4

TRANSACTIONS

LICENCES WITH UNIVERSITY BASED

ON REVENUE SHARING

RESEARCH AGREEMENT WITH

PRINCIPAL INVESTIGATOR

FINANCINGS

FEASABILITY FIRST $500K TO $1M

FOLLOW-ON$1.M TO 3M$

LEVERS

LAB INFRASTRUCTURE FROM PRINCIPAL

INVESTIGATOR

NON-DILUTIVE GRANTS

EXITS

LICENCE

START UP

Portfolio of technologies diversified across multiple disease indications

• PCSK9 sm• PCSK9 sdAb• CD36 CV

CARDIOLOGY

• DNMTI• AML

HEMATOLOGY

• AML• GVHD

DIAGNOSTICS

• MiHA• CD73

IMMUNO-ONCOLOY

• ABHD6

METABOLIC

• OXO ETE• S100A9• DUB

INFLAMMATION

• DM1• CFTR• FRATAXIN

ORPHAN

• CD36 AMD• SEMA3A• MNPs

OCULAR

• POROUS SCREW

• GREATER TROCANTER

ORTHOPEDIC DEVICES

In red are projects for which we have or will have intellectual property protection in China

5

Portfolio well diversified across stage of development

TARGET ID & VALIDATION

DUBCD36 AMDCD36 CVS100A9

HIT TO LEAD

PCSK9 SMPCKS9 SDABABHD6FRATAXINCD73

LEAD OP

DM1SEMA3A

PRE-CLINICAL

POROUS SCREWDNMTIOXO ETEGREATER TROCANTERMNPs

CLINICAL

MIHAGVHD DXAML DX

6

Exits

• Pharma– Roche (2014)– Vertex (2016)

• Spinouts– Mperia (CD36)– SemaThera (Sema 3a)– Corbin Therapeutics (DUBs)– SpecificiT Pharma (MiHA)

AmorChem II

• Financing – pan Canadian opportunities– First close in H1 2017 – $ 39M earmarked– Second close H1 2018 – looking for $40M

• Opportunities – welcome new LP’s– Invest ($5-10M) - first access to innovative

technology

Mucoadhesive Nanoparticles

• Technology – platform drug delivery, delivers drug from hrs. to 5 days, covalently binds to mucous membranes

• Objective – advance technology to IND enabling studies• Stage – dry eye PoC has been achieved• Next Steps - cGMP manufacturing, expand the potential of

the technology, feasibility testing of various molecules for partners

• Indications– Ocular - dry eye, glaucoma, conjunctivitis, uveitis, etc.– Other mucous membranes - respiratory, nasal, oral,

genital, etc.

Technology Description

• MNPs carry a large dose of ocular drug of choice

• MNPs establish strong covalent adhesion towards ocular mucous membrane

• MNPs release drugs at a sustained and tunable rate

• MNPs do not cause irritation due to nano-scale sizes

10

Long-lasting topical drops using mucoadhesive nanoparticles (MNPs)

Treatment of Experimental Dry Eye in Mice

Once weekly administration of cyclosporine A encapsulated MNPs eliminated inflammation and restored goblet cells in the treatment of dry eye.

11

Saline (1/wk.) MNP w. CycA (1.5 µg x 1/wk.)

Restasis(1.5 µg x 3/day)

• Inflammation (red arrows)

• Inflammation is eliminated

• Goblet cells are also restored

After one week of Dry Eye Syndrome treatment:

• Inflammation is eliminated

• No goblet cells

Semaphorin 3A TRAPS

• Technology – biologic, engineered protein targeting semaphorin 3A & VEGF

• Objective – demonstrate efficacy in diabetes related ocular diseases & vascular leakage

• Stage – lead optimization• Next Steps – select candidate for development, cGMP

manufacturing to enable in vivo & IND enabling studies• Potential indications

• Ocular (DME, DR, AMD)• Others – Acute kidney injury, diabetic nephropathy, stroke, concussion,

sepsis, oncology (prostate), immuno-oncology

DIABETIC RETINOPATHY| Semaphorin 3A

13

Mice (n=13) were injected intraperitoneally with 55mg STZ/kg body weight for 5 consecutive days.

STZ-treated diabetic mice have increased retinal expression of Sema3A

5-oxo-eteMost potent chemoattractant of eosinophils

• Technology – small molecule single digit, pM, oral bioavailable, good PK profile, scale-up & chiral synthesis

• Objective – antagonize eosinophilia• Stage – Candidate for development• Next Steps – primate experiments

– dermal – oxo-ete & house dust mite (completed)– Inhalation - house dust mite induced asthma model (on going)

• Potential Indications– Severe asthma, eosinophilic esophagitis, IBD, atopic dermatitis, VKC,

nasal polyps– Orphan – hyper-eosinophilic diseases

Thank you for your attention

I look forward to meeting & discussing potential relationships with you